Company Profile
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers develops, manufactures, and commercializes various medicines that improve patients' health in China.
It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases
Including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases. Its portfolio also includes FB4001, to treat patients with osteoporosis or high risk of fracture, and FB3002, for the treatment of pain in muscles, bones, and joints. Founded in 2002, Frontier Biotechnologies is headquartered in Nanjing, China.